目的 探討注射用重組人生長(zhǎng)激素聯(lián)合注射用頭孢曲松鈉治療患兒新生兒敗血癥的臨床療效。方法 選取2018年5月—2021年1月許昌市中心醫(yī)院收治的86例新生兒敗血癥患兒作為研究對(duì)象，根據(jù)隨機(jī)數(shù)字表法將86例患兒分為對(duì)照組和治療組，每組各43例。對(duì)照組患兒微泵靜脈滴注注射用頭孢曲松鈉20 mg/kg，1次/d。治療組在對(duì)照組治療的基礎(chǔ)上腹部肌注注射用重組人生長(zhǎng)激素，劑量0.1 IU/kg，1次/2 d。兩組患兒連續(xù)治療8 d。觀察兩組患兒的臨床療效，比較兩組患兒癥狀體征改善時(shí)間，以及血清中C反應(yīng)蛋白（CRP）、白細(xì)胞介素-6（IL-6）、降鈣素原（PCT）、CD4⁺/CD16⁺、CD3⁺、CD4⁺水平。結(jié)果 治療后，治療組的總有效率（95.35%）高于對(duì)照組（81.40%），組間差異有顯著性（P<0.05）。治療后，治療組的體溫恢復(fù)時(shí)間、拒奶消失時(shí)間、住院時(shí)間均明顯短于對(duì)照組（P<0.05）。治療后，兩組的血清CRP、IL-6、PCT水平明顯降低（P<0.05）；且治療組的血清CRP、IL-6、PCT水平低于對(duì)照組（P<0.05）。治療后，治療組的CD4⁺/CD16⁺較治療前顯著降低，CD3⁺、CD4⁺較治療前顯著升高（P<0.05）；治療組患者的CD4⁺/CD16⁺明顯低于對(duì)照組，CD3⁺、CD4⁺高于對(duì)照組（P<0.05）。結(jié)論 注射用重組人生長(zhǎng)激素聯(lián)合注射用頭孢曲松鈉可提高新生兒敗血癥的療效，有助于改善臨床癥狀，降低炎癥反應(yīng)，改善患兒的免疫功能，藥物安全性良好。

Objective To investigate the therapeutic effect of Recombinant Human Growth Hormone for injection combined with Ceftriaxone Sodium for injection in treatment of neonatal sepsis. Methods Children (86 cases) with neonatal sepsis in Xuchang Central Hospital from May 2018 to January 2021 were randomly divided into control and treatment groups, and each group had 43 cases. Children in the control group were micro pump intravenous drip administered with Ceftriaxone Sodium for injection, 20 mg/kg, once daily. Children in the treatment group were abdominal im administered with Recombinant Human Growth Hormone for injection on the basis of the control group, 0.1 IU/kg, once every 2 days. Children in two groups were treated for 8 d. After treatment, the clinical efficacies were evaluated, and the improvement time of symptom, and the levels of CRP, IL-6, PCT, CD4⁺/CD16⁺, CD3⁺, and CD4⁺ in two groups were compared. Results After treatment, the total effective rate of the treatment group (95.35%) was higher than that of the control group (81.40%), and there was significant differences between groups (P < 0.05). After treatment, the recovery time of body temperature, the disappearance time of milk refusal, and the length of hospital stay in the treatment group were shorter than those in the control group (P < 0.05). After treatment, serum levels of CRP, IL-6, and PCT in two groups were significantly decreased (P < 0.05). After treatment, the serum levels of CRP, IL-6, and PCT in the treatment group were lower than those in the control group (P < 0.05). After treatment, the CD4⁺/CD16⁺ in the treatment group was significantly lower than that before treatment, but the CD3⁺ and CD4⁺ in the treatment group were significantly higher than that before treatment (P< 0.05). And the CD4⁺/CD16⁺ in the treatment group was lower than that in the control group, but the CD3⁺ and CD4⁺ in the treatment group were higher than those in the control group (P < 0.05). Conclusion Recombinant Human Growth Hormone for injection combined with Ceftriaxone Sodium for injection can improve the curative effect of neonatal sepsis, help to improve clinical symptoms, reduce inflammatory reaction, improve children's immune function, with good safety.

R973;R985

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃（聯(lián)合共建項(xiàng)目）（LHGJ20191401）